Reframing Head and Neck Cancer Costs—Insights from Screening in Taiwan
To the Editor Villemure-Poliquin et al1 identify stage and multimodality treatment as the strongest factors associated with high first-year costs in head and neck cancer. We commend the population-based approach, but 3 issues merit clarification and qualification.
Authors
- Sheng‐Dean Luo (ORCID: https://orcid.org/0000-0003-4095-5541)
- Wei‐Chih Chen (ORCID: https://orcid.org/0000-0003-4172-5529)
- Ching‐Nung Wu (ORCID: https://orcid.org/0000-0001-9397-0986)
Institutions
- National Sun Yat-sen University (TW)
- Chang Gung University (TW)
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Kaohsiung Municipal Ta-Tung Hospital (TW)
Publication Details
- Journal
- JAMA Otolaryngology–Head & Neck Surgery
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1001/jamaoto.2025.4133
- Citations
- 1
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.85